Extension of the RENACER Study: 12-Month Efficacy, Safety and Certolizumab PEGol Survival in 501 Rheumatoid Arthritis Patients Vicenç Torrente-Segarra, Manuel Fernández Prada, Rosa Expósito, Noemí Patricia Garrido Puñal, Amalia Sánchez-Andrade, José Ramón Lamúa-Riazuelo, Alejandro Olivé, Juan Víctor Tovar

Certolizumab Pegol-induced Palmoplantar Pustulosis: A Case Report and Review of the Literature Lourdes Villalobos-Sánchez, Carmen Larena-Grijalba, Adela Alía-Jiménez, Walter Alberto Sifuentes-Giraldo

Clinical, Patient-Reported, and Ultrasound Outcomes from an Open-Label, 12-week Observational Study of Certolizumab Pegol in Spanish Patients with Rheumatoid Arthritis with or without Prior Anti-TNF Exposure Francisco J. Blanco, Esteban Rubio-Romero, Raimon Sanmartí, César Díaz-Torné, Pablo Talavera, Jochen Dunkel, Esperanza Naredo